Effects of partial suppression of parkin on huntingtin mutant R6/1 mice

Brain Research

Volumn 1281, Issue , 2009, Pages 91-100

  Rubio, Isabel ^a,b   Rodríguez Navarro, José Antonio ^a   Tomás Zapico, Cristina ^b,c   Ruíz, Carolina ^a   Casarejos, María José ^a   Perucho, Juan ^a,b   Gómez, Ana ^a   Rodal, Izaskun ^a   Lucas, José J ^b,c   Mena, María Angeles ^a   de Yébenes, Justo García ^a,b  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c CSIC   (Spain)

Author keywords

Apoptosis; Autophagy; Dopamine neurons; Huntington's disease; Park 2 gene; Ubiquitin proteosomal system

Indexed keywords

HEAT SHOCK PROTEIN 70; HUNTINGTIN; MONOAMINE; PARKIN; PHOSPHOPROTEIN DARPP 32;

AKINESIA; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTOPHAGY; COMPARATIVE STUDY; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; EXPLORATORY BEHAVIOR; FEMALE; GENE DELETION; HIPPOCAMPUS; HISTOLOGY; MALE; MOUSE; NEUROCHEMISTRY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; WILD TYPE;

ANIMALS; BIOGENIC MONOAMINES; BRAIN; CELL DEATH; DISEASE MODELS, ANIMAL; DOPAMINE; EXPLORATORY BEHAVIOR; HSP70 HEAT-SHOCK PROTEINS; HUMANS; HUNTINGTON DISEASE; MALE; MICE; MICE, KNOCKOUT; MICE, MUTANT STRAINS; MICROTUBULE-ASSOCIATED PROTEINS; MOTOR ACTIVITY; NERVE TISSUE PROTEINS; NEURONS; NUCLEAR PROTEINS; PHENOTYPE; UBIQUITIN-PROTEIN LIGASES;

MUS;

EID: 67649411510     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2009.05.039     Document Type: Article

References (28)

1. Bence N.F., Sampat R.M., and Kopito R.R. Impairment of the ubiquitin-proteasome system by protein aggregation. Science 292 5521 (2001) 1552-1555
2. Bennett E.J., Shaler T.A., Woodman B., Ryu K.Y., Zaitseva T.S., Becker C.H., Bates G.P., Schulman H., and Kopito R.R. Global changes to the ubiquitin system in Huntington's disease. Nature 448 7154 (2007) 704-708
3. Carlsson A., and Lindqvist M. Effect of ethanol on the hydroxylation of tyrosine and tryptophan in rat brain in vivo. J. Pharm. Pharmacol. 25 6 (1973) 437-440
4. Garcia Ruiz P.J., Mena M.A., Sanchez Bernardos V., Diaz Neira W., Gimenez Roldan S., Benitez J., and Garcia de Yebenes J. Cerebrospinal fluid homovanillic acid is reduced in untreated Huntington's disease. Clin. Neuropharmacol. 18 1 (1995) 58-63
5. Gonzalez S., Mena M.A., Lastres-Becker I., Serrano A., de Yebenes J.G., Ramos J.A., and Fernandez-Ruiz J. Cannabinoid CB(1) receptors in the basal ganglia and motor response to activation or blockade of these receptors in parkin-null mice. Brain Res. 1046 1-2 (2005) 195-206
6. Gusella J.F., and Macdonald M.E. Huntington's disease: seeing the pathogenic process through a genetic lens. Trends Biochem. Sci. 31 9 (2006) 533-540
7. Hoenicka J., Vidal L., Morales B., Ampuero I., Jimenez-Jimenez F.J., Berciano J., del Ser T., Jimenez A., Ruiz P.G., and de Yebenes J.G. Molecular findings in familial Parkinson disease in Spain. Arch. Neurol. 59 6 (2002) 966-970
8. Hunter J.M., Lesort M., and Johnson G.V. Ubiquitin-proteasome system alterations in a striatal cell model of Huntington's disease. J. Neurosci. Res. 85 8 (2007) 1774-1788
9. Itier J.M., Ibanez P., Mena M.A., Abbas N., Cohen-Salmon C., Bohme G.A., Laville M., Pratt J., Corti O., Pradier L., Ret G., Joubert C., Periquet M., Araujo F., Negroni J., Casarejos M.J., Canals S., Solano R., Serrano A., Gallego E., Sanchez M., Denefle P., Benavides J., Tremp G., Rooney T.A., Brice A., and Garcia de Yebenes J. Parkin gene inactivation alters behaviour and dopamine neurotransmission in the mouse. Hum. Mol. Genet. 12 18 (2003) 2277-2291
10. Keller J.N., Hanni K.B., and Markesbery W.R. Impaired proteasome function in Alzheimer's disease. J. Neurochem. 75 1 (2000) 436-439
11. Khan L.A., Bauer P.O., Miyazaki H., Lindenberg K.S., Landwehrmeyer B.G., and Nukina N. Expanded polyglutamines impair synaptic transmission and ubiquitin-proteasome system in Caenorhabditis elegans. J. Neurochem. 98 2 (2006) 576-587
12. Kitada T., Asakawa S., Hattori N., Matsumine H., Yamamura Y., Minoshima S., Yokochi M., Mizuno Y., and Shimizu N. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392 6676 (1998) 605-608
13. Lim K.L., Dawson V.L., and Dawson T.M. Parkin-mediated lysine 63-linked polyubiquitination: a link to protein inclusions formation in Parkinson's and other conformational diseases?. Neurobiol. Aging 27 4 (2006) 524-529
14. Lucking C.B., Durr A., Bonifati V., Vaughan J., De Michele G., Gasser T., Harhangi B.S., Meco G., Denefle P., Wood N.W., Agid Y., and Brice A. Association between early-onset Parkinson's disease and mutations in the parkin gene. N. Engl. J. Med. 342 21 (2000) 1560-1567
15. Mangiarini L., Sathasivam K., Seller M., Cozens B., Harper A., Hetherington C., Lawton M., Trottier Y., Lehrach H., Davies S.W., and Bates G.P. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87 3 (1996) 493-506
16. Marchut A.J., and Hall C.K. Effects of chain length on the aggregation of model polyglutamine peptides: molecular dynamics simulations. Proteins 66 1 (2007) 96-109
17. Morales B., Martinez A., Gonzalo I., Vidal L., Ros R., Gomez-Tortosa E., Rabano A., Ampuero I., Sanchez M., Hoenicka J., and Garcia De Yebenes J. Steele-Richardson-Olszewski syndrome in a patient with a single C212Y mutation in the parkin protein. Mov. Disord. 17 6 (2002) 1374-1380
18. Ortega Z., Diaz-Hernandez M., and Lucas J.J. Is the ubiquitin-proteasome system impaired in Huntington's disease?. Cell. Mol. Life Sci. 64 17 (2007) 2245-2257
19. Paul S. Polyglutamine-mediated neurodegeneration: use of chaperones as prevention strategy. Biochemistry (Mosc) 72 4 (2007) 359-366
20. Rodriguez-Navarro J.A., Casarejos M.J., Menendez J., Solano R.M., Rodal I., Gomez A., Yebenes J.G., and Mena M.A. Mortality, oxidative stress and tau accumulation during ageing in parkin null mice. J. Neurochem. 103 1 (2007) 98-114
21. Ros R., Ampuero I., and Garcia de Yebenes J. Parkin polymorphisms in progressive supranuclear palsy. J. Neurol. Sci. 268 1-2 (2008) 176-178
22. Ross C.A., and Pickart C.M. The ubiquitin-proteasome pathway in Parkinson's disease and other neurodegenerative diseases. Trends Cell Biol. 14 12 (2004) 703-711
23. Serrano A., Menendez J., Casarejos M.J., Solano R.M., Gallego E., Sanchez M., Mena M.A., and Garcia de Yebenes J. Effects of cinnarizine, a calcium antagonist that produces human parkinsonism, in parkin knock out mice. Neuropharmacology 49 2 (2005) 208-219
24. Solans A., Zambrano A., Rodriguez M., and Barrientos A. Cytotoxicity of a mutant huntingtin fragment in yeast involves early alterations in mitochondrial OXPHOS complexes II and III. Hum. Mol. Genet. 15 20 (2006) 3063-3081
25. Tietze F. Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: applications to mammalian blood and other tissues. Anal. Biochem. 27 3 (1969) 502-522
26. Valera A.G., Diaz-Hernandez M., Hernandez F., Ortega Z., and Lucas J.J. The ubiquitin-proteasome system in Huntington's disease. Neuroscientist 11 6 (2005) 583-594
27. Wang J., Wang C.E., Orr A., Tydlacka S., Li S.H., and Li X.J. Impaired ubiquitin-proteasome system activity in the synapses of Huntington's disease mice. J. Cell Biol. 180 6 (2008) 1177-1189
28. Zhai W., Jeong H., Cui L., Krainc D., and Tjian R. In vitro analysis of huntingtin-mediated transcriptional repression reveals multiple transcription factor targets. Cell 123 7 (2005) 1241-1253